8 octubre 2015
For the first time, researchers have shown that the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
http://www.sciencedaily.com/releases/2015/10/151008101434.htm
